Document is current
Any future updates will be listed below
-
Authors
Carda, José https://orcid.org/0000-0002-8198-9812
Martins, Ângelo
Alves, Daniela
Gomes, Marília https://orcid.org/0000-0002-8633-6941
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 10 September 2025
First Online: 25 September 2025
Declarations
:
: J.C. has received travel grants from AbbVie, Janssen, Roche, Takeda, Gilead, and Beigene. In addition, J.C. has served as a consultant and/or on the scientific advisory boards for AbbVie, Janssen, Roche, Takeda, Sanofi, BeiGene, Gilead, AstraZeneca, and Lilly. A.M. declares that there are no conflicts of interest to disclose. D.A. has served as a consultant/advisor for AbbVie, Takeda, AstraZeneca, Roche, Lilly, Janssen-Cilag, Incyte, and Gilead. D.A. has also received lecture fees from and participated in speakers’ bureaus for Janssen-Cilag, AbbVie, Takeda, AstraZeneca, Gilead, Roche, and EUSA Pharma. Additionally, D.A. is a principal investigator in clinical trials sponsored by Sanofi, Janssen-Cilag, AstraZeneca, Kartos Therapeutics, BeiGene, AbbVie, and Merck Sharp & Dohme. M.G. has received compensation for consulting services from AbbVie, AstraZeneca, Janssen-Cilag, and Takeda. As a speaker, M.G. has presented on behalf of AbbVie, Roche, Gilead, Janssen-Cilag, and Takeda. Support for participation in congresses has been provided by AbbVie, Roche, Gilead, Beigene, Janssen-Cilag, and Takeda. Additionally, M.G. has participated in expert panels for AbbVie, AstraZeneca, Lilly, Roche, Gilead, Beigene, and Takeda.
: Not applicable.
